A dose escalation/expansion study evaluating dose, safety, and efficacy of the novel tyrosine kinase inhibitor surufatinib, which inhibits VEGFR 1, 2, & 3, FGFR 1, and CSF1R, in US patients with neuroendocrine tumors

Surufatinib, is a potent inhibitor of vascular endothelial growth factor receptors 1–3; fibroblast growth factor receptor-1; colony-stimulating factor 1 receptor. This Phase 1/1b escalation/expansion study in US patients with solid tumors evaluated 5 once daily (QD) surufatinib doses (3 + 3 design)...

Descripción completa

Detalles Bibliográficos
Autores principales: Dasari, Arvind, Hamilton, Erika P., Falchook, Gerald S., Wang, Judy S., Li, Daneng, Sung, Max W., Chien, Caly, Nanda, Shivani, Tucci, Christopher, Hahka-Kemppinen, Marjo, Paulson, Andrew Scott
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer US 2023
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10289989/
https://www.ncbi.nlm.nih.gov/pubmed/37074571
http://dx.doi.org/10.1007/s10637-023-01359-2

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10289989/
https://www.ncbi.nlm.nih.gov/pubmed/37074571
http://dx.doi.org/10.1007/s10637-023-01359-2

Ejemplares similares